MacuLogix recently announced that it has entered an international distribution agreement with Canada-based Clarion Medical Technologies. Through the agreement Clarion will add the AdaptDx automated dark adaptometer to its vision products.
“We are very pleased to partner with Clarion to expand our reach into Canada,” Armond Dantino, VP of sales for MacuLogix, said in a press release. “Bringing the AdaptDx to Canada is critical to preserving vision, as AMD accounts for 90% of new cases of legal blindness in Canada, according to the Canadian Ophthalmological Society.”
AdaptDx is a dark adaptometer that is used in clinical practice to detect age-related macular degeneration (AMD) at a subclinical stage before structural changes in the retina are visible.
“The AdaptDx is an exciting addition to Clarion’s expansive portfolio of revolutionary ophthalmic devices, lenses and nutraceuticals,” said Dan Webb, chairman of Clarion Medical Technologies. “We take great pride in offering cutting-edge technology solutions to our vision customers and are confident that Canadian eye care professional will find great value in the AdaptDx for detecting the monitoring age-related macular degeneration.”
